PE20090831A1 - Anticuerpo monoclonal - Google Patents
Anticuerpo monoclonalInfo
- Publication number
- PE20090831A1 PE20090831A1 PE2008001009A PE2008001009A PE20090831A1 PE 20090831 A1 PE20090831 A1 PE 20090831A1 PE 2008001009 A PE2008001009 A PE 2008001009A PE 2008001009 A PE2008001009 A PE 2008001009A PE 20090831 A1 PE20090831 A1 PE 20090831A1
- Authority
- PE
- Peru
- Prior art keywords
- amylomended
- peptides
- antibody
- seq
- chain
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
Abstract
SE REFIERE A UN ANTICUERPO MONOCLONAL QUE INCLUYE CUALQUIER ANTICUERPO FUNCIONALMENTE EQUIVALENTE O SUS PARTES FUNCIONALES, QUE RECONOCE UN EPITOPE CONFORMACIONAL, Y QUE SE UNE A PEPTIDOS Aß AMILOIDES SOLUBLES POLIMERICOS Y A PEPTIDOS Aß AMILOIDES OLIGOMERICOS QUE COMPRENDEN UNA PLURALIDAD DE PEPTIDOS Aß1-42 MONOMERICOS. DICHO ANTICUERPO COMPRENDE UN DOMINIO VARIABLE DE CADENA PESADA Y DE CADENA LIVIANA QUE EXHIBE UNA SECUENCIA DE AMINOACIDOS QUE ES DE 85% A 99% IDENTICAS A LA SEQ ID N°7 Y SEQ ID N° 8, O UNA PARTE FUNCIONAL DE ESTA QUE COMPRENDE UNA PARTE O LA TOTALIDAD DE LAS CDR DE CADENA LIVIANA Y DE CADENA PESADA QUE CONTIENEN LAS SECUENCIAS DE POLIPEPTIDOS SEQ ID N° 9-14. SE REFIERE TAMBIEN A UN METODO DE PRODUCCION Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO ANTICUERPO SIENDO UTIL PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS CAUSADOS O ASOCIADOS A LAS PROTEINAS AMILOIDES O SIMILARES QUE INCLUYEN LA AMILOIDOSIS, ENFERMEDAD DE ALZHEIMER, SINDROME DE DOWN
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94354107P | 2007-06-12 | 2007-06-12 | |
| US94354307P | 2007-06-12 | 2007-06-12 | |
| US94379007P | 2007-06-13 | 2007-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090831A1 true PE20090831A1 (es) | 2009-07-10 |
Family
ID=39790376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001009A PE20090831A1 (es) | 2007-06-12 | 2008-06-12 | Anticuerpo monoclonal |
| PE2013000112A PE20131141A1 (es) | 2007-06-12 | 2008-06-12 | Anticuerpo monoclonal |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000112A PE20131141A1 (es) | 2007-06-12 | 2008-06-12 | Anticuerpo monoclonal |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP2170953B1 (es) |
| JP (2) | JP5436414B2 (es) |
| KR (2) | KR101600095B1 (es) |
| CN (1) | CN101802007B (es) |
| AR (1) | AR066987A1 (es) |
| AU (1) | AU2008267037B2 (es) |
| BR (1) | BRPI0812484A2 (es) |
| CA (1) | CA2690434C (es) |
| CL (3) | CL2008001742A1 (es) |
| ES (1) | ES2548102T3 (es) |
| IL (1) | IL202563A (es) |
| MX (1) | MX2009013503A (es) |
| NZ (2) | NZ581835A (es) |
| PE (2) | PE20090831A1 (es) |
| RU (1) | RU2571856C2 (es) |
| TW (2) | TWI453217B (es) |
| WO (1) | WO2008156621A1 (es) |
| ZA (1) | ZA201000049B (es) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| CA2628703C (en) | 2005-11-30 | 2019-10-29 | Abbott Laboratories | Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| EP1976877B2 (en) | 2005-11-30 | 2016-10-05 | AbbVie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
| TWI551607B (zh) | 2006-07-14 | 2016-10-01 | Ａｃ免疫公司 | 人類化抗體 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| TWI453217B (zh) * | 2007-06-12 | 2014-09-21 | Ac Immune Sa | 抗β類澱粉蛋白單株抗體 |
| SG10201505369QA (en) * | 2007-10-05 | 2015-08-28 | Genentech Inc | Use of anti-amyloid beta antibody in ocular diseases |
| GB0903325D0 (en) * | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| MX2012009460A (es) | 2010-03-03 | 2012-09-12 | Boehringer Ingelheim Int | Polipeptidos biparatopicos de union abeta. |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| KR101713365B1 (ko) | 2010-07-30 | 2017-03-08 | 에이씨 이뮨 에스.에이. | 안전하고 기능적인 인간화 항 베타-아밀로이드 항체 |
| MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
| SI2646470T1 (sl) | 2010-11-30 | 2017-05-31 | F. Hoffmann-La Roche Ag | Protitelesa proti receptorjem antitransferina in njihova uporaba za prenos terapevtskega enoverižnega variabilnega fragmenta (scfv) prek krvno-možganske pregrade |
| CN103443277B (zh) | 2011-02-18 | 2016-02-24 | 国立大学法人东京农工大学 | 淀粉样蛋白低聚物结合核酸适体 |
| WO2013020372A1 (zh) * | 2011-08-09 | 2013-02-14 | 中国科学院上海生命科学研究院 | 防治胰岛素抵抗和糖尿病的方法和试剂 |
| CA2811188C (en) * | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
| WO2013177062A2 (en) | 2012-05-21 | 2013-11-28 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| JP6612214B2 (ja) | 2013-05-20 | 2019-11-27 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体抗体及び使用方法 |
| SG10201802525QA (en) | 2013-09-13 | 2018-04-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| EP3044323B1 (en) | 2013-09-13 | 2022-04-06 | F. Hoffmann-La Roche AG | Methods for detecting and quantifying host cell protein in cell lines |
| JP6779876B2 (ja) | 2014-11-19 | 2020-11-04 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
| JP6861418B2 (ja) | 2015-09-02 | 2021-04-28 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体 |
| JP7452829B2 (ja) | 2015-11-09 | 2024-03-19 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | アミロイドベータのエピトープおよびそれに対する抗体 |
| US10774120B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
| JP6994469B2 (ja) * | 2016-04-20 | 2022-02-04 | エアラン セル テクノロジーズ， インコーポレイテッド | Ｋ１８０ジメチル化ｈ１．０タンパク質に関連する組成物および方法 |
| AU2017299858B2 (en) | 2016-07-18 | 2024-07-25 | Promis Neurosciences, Inc. | Antibodies to Amyloid beta |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
| WO2020025066A1 (en) * | 2018-08-03 | 2020-02-06 | The University Of Hong Kong | Compositions and methods for detection and imaging of amyloid fibrils, amyloid plaques, rna, and nucleoli |
| KR101977410B1 (ko) * | 2018-08-22 | 2019-05-10 | 주식회사 피플바이오 | 당뇨병에 대한 신규 바이오마커 및 그의 용도 |
| US12016885B2 (en) | 2018-11-06 | 2024-06-25 | Alsatech, Inc. | Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab |
| CN111518205B (zh) * | 2019-02-01 | 2022-03-29 | 长春金赛药业有限责任公司 | 人源化抗Aβ单克隆抗体及其应用 |
| CN111518206B (zh) | 2019-02-01 | 2022-03-29 | 长春金赛药业有限责任公司 | 人源化抗Aβ单克隆抗体及其应用 |
| EP3757125A1 (en) * | 2019-06-28 | 2020-12-30 | BioArctic AB | Antibody directed against the apoe amino-terminal fragment of 12 kda |
| CN110317814A (zh) * | 2019-07-19 | 2019-10-11 | 莫丁丁 | β-淀粉样蛋白环状核糖核酸、多肽及其应用 |
| WO2021048324A1 (en) * | 2019-09-10 | 2021-03-18 | Ac Immune Sa | Novel molecules for diagnosis |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| CN110687035A (zh) * | 2019-10-10 | 2020-01-14 | 沈阳万类生物科技有限公司 | Annexin V-Light 650凋亡检测试剂盒 |
| CN113884683A (zh) * | 2020-07-30 | 2022-01-04 | 山东京济生物工程有限公司 | 一种快速检测Aβ42的双抗体夹心ELISA试剂盒 |
| CN113308439B (zh) * | 2020-11-06 | 2023-05-05 | 华中科技大学 | 分泌人淀粉样蛋白-β单克隆抗体的杂交瘤细胞株及其应用 |
| CN112540180B (zh) * | 2020-11-06 | 2022-03-29 | 华中科技大学 | 用于检测人淀粉样蛋白-β双抗夹心ELISA检测试剂盒 |
| CN113057963B (zh) * | 2021-03-31 | 2022-05-20 | 华中科技大学 | 一种用于清除β-淀粉样蛋白的特异性捕获载体及其应用 |
| CN113311153B (zh) * | 2021-05-12 | 2023-05-26 | 华中科技大学 | 一种用于阿尔茨海默病诊疗一体化的多功能的纳米粒子 |
| CN113603773B (zh) * | 2021-08-17 | 2023-05-09 | 中国医科大学附属第一医院 | 靶向淀粉样蛋白的单克隆抗体7b8、分泌该抗体的杂交瘤细胞株及应用 |
| CN114591429B (zh) * | 2022-05-07 | 2022-08-09 | 北京第一生物化学药业有限公司 | 结合β-淀粉样蛋白的抗体及其用途 |
| KR102565470B1 (ko) * | 2022-08-04 | 2023-08-10 | 가천대학교 산학협력단 | 아밀로이드 베타 특이적 펩타이드 sma_04088-2 및 이를 포함하는 알츠하이머병 치료용 조성물 |
| KR102565471B1 (ko) * | 2022-08-04 | 2023-08-10 | 가천대학교 산학협력단 | 아밀로이드 베타 특이적 펩타이드 cbrv1-04369 및 이를 포함하는 알츠하이머병 치료용 조성물 |
| CN117586370A (zh) * | 2022-08-09 | 2024-02-23 | 深圳智源生物医药有限公司 | 强毒性淀粉样蛋白寡聚体及其用途 |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
| CN119390832A (zh) * | 2024-10-12 | 2025-02-07 | 中国科学技术大学 | 一种兔源Aβ 1-40单克隆抗体、制备方法及应用 |
| CN120098147B (zh) * | 2025-05-07 | 2025-07-15 | 中山大学 | 一种纳米自组装抗Aβ抗体及其制备方法和应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20030229208A1 (en) * | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| EP0652775B1 (en) | 1992-07-27 | 2000-04-19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Targeting of liposomes to the blood-brain barrier |
| ZA938243B (en) * | 1992-11-12 | 1995-05-04 | Hybritech Inc | Altered affinity polypeptides of metal chelate binding antibodies |
| CA2127476C (en) | 1994-07-06 | 1999-12-07 | Daniel G. Pomerleau | Logging or measurement while tripping |
| AU702436B2 (en) | 1994-10-21 | 1999-02-18 | Innogenetics N.V. | New sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| WO1997010505A1 (en) * | 1995-09-14 | 1997-03-20 | The Regents Of The University Of California | ANTIBODIES SPECIFIC FOR NATIVE PrP?Sc¿ |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| AU8470301A (en) | 2000-08-03 | 2002-02-18 | Wim-Van Schooten | Production of humanized antibodies in transgenic animals |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| DE60234057D1 (de) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
| EP1420032B2 (en) * | 2001-08-03 | 2015-12-16 | Medical & Biological Laboratories Co., Ltd. | Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody |
| CN100488982C (zh) * | 2001-11-02 | 2009-05-20 | 迪尔基因国际有限公司 | 与β-淀粉样蛋白结合并引起蛋白质构象转变的单克隆抗体的制备方法 |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7220833B2 (en) | 2002-12-03 | 2007-05-22 | Thomas Nelson | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| EA012325B1 (ru) | 2002-12-24 | 2009-08-28 | Беллус Хелс (Интернэшнл) Лимитед | Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида |
| WO2004065569A2 (en) * | 2003-01-23 | 2004-08-05 | The Regents Of The University Of California | Multi-functional antibodies |
| DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US8663650B2 (en) * | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| JP2007505142A (ja) | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| JP4870348B2 (ja) * | 2003-12-04 | 2012-02-08 | 株式会社ペルセウスプロテオミクス | 細胞表面抗原に対する抗体取得とその抗原同定 |
| MX2007000998A (es) * | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| EP2269633A1 (en) | 2005-05-05 | 2011-01-05 | Merck Sharp & Dohme Corp. | Peptide conjugate compositions and methods for the prevention and treatment of Alzheimer's disease |
| EP2594591B1 (en) * | 2005-08-11 | 2018-06-06 | Arpi Matossian-Rogers | Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease |
| AU2006301492B2 (en) * | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
| EP1976877B2 (en) * | 2005-11-30 | 2016-10-05 | AbbVie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
| US20070237764A1 (en) * | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| TWI453217B (zh) * | 2007-06-12 | 2014-09-21 | Ac Immune Sa | 抗β類澱粉蛋白單株抗體 |
-
2008
- 2008-06-12 TW TW097122016A patent/TWI453217B/zh active
- 2008-06-12 PE PE2008001009A patent/PE20090831A1/es active IP Right Grant
- 2008-06-12 WO PCT/US2008/007317 patent/WO2008156621A1/en not_active Ceased
- 2008-06-12 NZ NZ581835A patent/NZ581835A/xx unknown
- 2008-06-12 KR KR1020107000699A patent/KR101600095B1/ko active Active
- 2008-06-12 AR ARP080102521A patent/AR066987A1/es not_active Application Discontinuation
- 2008-06-12 AU AU2008267037A patent/AU2008267037B2/en active Active
- 2008-06-12 TW TW103117223A patent/TWI516500B/zh active
- 2008-06-12 NZ NZ601843A patent/NZ601843A/en unknown
- 2008-06-12 MX MX2009013503A patent/MX2009013503A/es active IP Right Grant
- 2008-06-12 BR BRPI0812484A patent/BRPI0812484A2/pt not_active IP Right Cessation
- 2008-06-12 CA CA2690434A patent/CA2690434C/en active Active
- 2008-06-12 EP EP08768370.2A patent/EP2170953B1/en active Active
- 2008-06-12 EP EP12167447.7A patent/EP2527366B1/en active Active
- 2008-06-12 JP JP2010512181A patent/JP5436414B2/ja active Active
- 2008-06-12 PE PE2013000112A patent/PE20131141A1/es active IP Right Grant
- 2008-06-12 ES ES08768370.2T patent/ES2548102T3/es active Active
- 2008-06-12 RU RU2010100354/10A patent/RU2571856C2/ru active
- 2008-06-12 CL CL2008001742A patent/CL2008001742A1/es unknown
- 2008-06-12 CN CN200880103203.6A patent/CN101802007B/zh active Active
- 2008-06-12 KR KR1020167002381A patent/KR20160017126A/ko not_active Withdrawn
-
2009
- 2009-12-07 IL IL202563A patent/IL202563A/en active IP Right Grant
-
2010
- 2010-01-04 ZA ZA2010/00049A patent/ZA201000049B/en unknown
-
2012
- 2012-03-09 CL CL2012000631A patent/CL2012000631A1/es unknown
- 2012-07-04 CL CL2012001817A patent/CL2012001817A1/es unknown
-
2013
- 2013-12-10 JP JP2013254631A patent/JP2014087353A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090831A1 (es) | Anticuerpo monoclonal | |
| AR069130A1 (es) | Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| PE20141186A1 (es) | Proteinas de union al tnf-alfa | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| PE20140448A1 (es) | Moleculas de union biespecificas que se unen a vegf y ang2 | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| PE20131376A1 (es) | Anticuerpos para metaloproteinasa-9 de matriz | |
| EA200970694A1 (ru) | ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ | |
| ES2570853T3 (es) | Moléculas de anticuerpo humanizadas específicas para IL-31 | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| PE20190261A1 (es) | Anticuerpos que reconocen tau | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| PE20170912A1 (es) | Conjugados de anticuerpo-farmaco | |
| CO6231009A2 (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| NZ629829A (en) | Anti-c5a antibodies and methods for using the antibodies | |
| PE20131334A1 (es) | Anticuerpo igg1 humanizado | |
| CL2018001238A1 (es) | Moléculas de unión específicas para asct2 y usos de las mismas | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| JP2016531546A5 (es) | ||
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |